# PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR γ (PPARγ) IS REGULATOR OF COLORECTAL CANCER CELL GROWTH AND DIFFERENTIATION

By

Rajnish Anand Gupta

Dissertation

Submitted to the Faculty of the Graduate School of Vanderbilt University in partial fulfillment of the requirements for the degree of

#### DOCTOR OF PHILOSOPHY

in

Cell Biology

May, 2004

Approved By: Professor Raymond N. DuBois Professor Al Reynolds Professor Stephen J. Brandt

#### ACKNOWLEDGEMENTS

I would like to thank my mother and father, my sister Archana, and my brother Shailen for their unconditional support and encouragement. I would like to thank my graduate thesis advisor, Dr. Raymond DuBois, for all his support, guidance, and patience over the last four years. I have learned a great deal from him, including the importance of identifying meaningful research problems and on how one can successfully integrate clinical and basic science as a physician-scientist. I would also like to thank the members of my thesis advisory committee, Drs. Reynolds, Brandt, Granner, Magnuson, and Crawford for their support and guidance and for always willing to meet with me to discuss my work. All members of the DuBois lab (past and present) provided me with a great deal of help during the last four years, including Jeff Brockman, Chris Williams, Rebecca Shattuck-Brandt, Wade Krause, Sharada Katkuri, Hongmiao Sheng, Jinyi Shao, Radhika Aramandala, and Zhounghou Zhang. I would in particular like to thank Howard Crawford, whose bench was down the hall from mine and who was always willing to take the time to teach me and help me with my research the many times I wandered down to talk with him. Finally, Pasha Sarraf (Dana Farber Cancer Institute), S. K. Dey (University of Kansas), and Tim Willson (GlaxoSmithKline) were all collaborators on various projects and their involvement has been extremely beneficial to me.

#### TABLE OF CONTENTS

F	Page
ACKNOWLEDGEMENTS	
LIST OF TABLES v	vi
LIST OF FIGURES v	vii
Chapter	
Chapter	
I. INTRODUCTION	1
Introduction to the nuclear hormone receptor superfamily.1NHR binding motifs – the hormone response element.2Classification of NHRs.2Structure of NHRs.2Transcriptional activities of NHRs.8The role of coregulators in NHR function.9NHR coactivators.1NHR corepressors.1The coregulator exchange in NHR function.1Introduction to peroxisome proliferator-activated receptors.1Overview of PPARa.1Overview of PPARq.1Introduction to PPARq.2PPARq ligands.2PPARq as a regulator of adipocyte differentiaoin.2PPARq and the control of cell cycle.2PPARq and the control of cell cycle.2PPARq and the control of cell cycle.2PPARq and the control of cell cycle.2Cyclooxygenases and colorectal cancer.2Cyclooxygenase and prostaglandin synthesis.2A second cyclooxygenase enzyme.3NSAIDs and colorectal cancer.3How does COX-2 promote tumor development.3Summary.3	1 2 2 5 3 11 12 13 14 18 19 20 23 24 25 27 28 29 31 32 33 34 36
II. METHODS 3	38
Cell culture.3Nuclear receptor ligands.3Plasmids.3RT-PCR for PPAR subtypes.4Antibodies.4Western blot analysis.4	38 38 39 40 41 41

	Detection of PPARγ protein by IP/Western blot	42
	Transient transfections	42
	Luciferase assays	43
	Cell growth measurements	43
	Anchorage independent growth assay	43
	Tumor growth in athymic mice	44
	Flow cytometry	44
	cDNA microarray screening	
	Oligonucleotide microarray screening	
	Northern blot hybridization	46
	cDNA probes for northern blots	48
	Cell aggregation assay	48
	PPARy gene mutation detection	40 49
	Flectromobility shift assay	49 40
	Mammalian two hybrid	+) 50
	Generation of stable call lines using retroviral infaction	50
	Concretion of stable cell lines using reliovital infection.	50
		JI 51
		51
	In situ hybridization	
111.	ACTIVATION OF PPARY INHIBITS COLORECTAL	50
	CANCER CELL GROWTH	53
	The state of the s	50
	Introduction	53
	Results	54
	PPARγ expression and transcriptional activity in	
	a panel of human colorectal cancer cell lines	54
	Activation of PPAR <sub>γ</sub> inhibits human colorectal cancer	
	cell growth <i>in vivo</i>	58
	Activation of PPARy delays cell cycle progression	61
	Conclusion	61
IV.	TARGET GENES OF PPARγ IN COLORECTAL	
	CANCER CELLS.	62
	Introduction	62
	Results	64
	Evaluation of a cell culture system to monitor	
	PPARv target genes	64
	Identification of PPARy target genes using microarrays.	
	Characterizing the specificity and selectivity of each	• 1
	target gene induction/repression	69
	Activation of PPARy induces an increase in CFA-	07
	dependent homotypic aggregation	72
	Conclusion	72
	Conclusion	15
$\mathbf{V}$	Δ Ι Ωςς ΟΕ ΕΠΝΟΤΙΩΝ ΡΡΔΡγ ΔΙ Ι ΕΙ Ε ΙΝ ΟΩΙ ΩΡΕΟΤΔΙ	
v.	CANCER CELLS CAUSED BY A MUTATION THAT	
	DISDUDTS BASAL TO ANSCHIDTIONAL DEDDESSION	77
	DISKULIS DASAL INAUSUNII HUIVAL NEENESSIUV	//
	Introduction	77
	Introduction	//
	DDA Du ligand consitivity and DDA Du conservations in	19
	Praky ligand sensitivity and Praky gene mutations in $\alpha$	70
	a panel of numan colorectal cancer cell lines	/9

	Characterization of K422Q mutant allele
VI.	PPARγ AND TRANSFORMING GROWTH FACTOR β PATHWAYS INHIBIT COLON EPITHELIAL CELL GROWTH BY REGULATING LEVELS OF TSC-22
	Introduction
	Identification of TSC-22 as a PPAR $\gamma$ and TGF- $\beta$ target gene in
	Transcriptional regulation of TSC-22 by PPARγ and
	TGF- $\beta$ 1
	independent of $TGF-\beta1$
	epithelial cell growth and induces elevated levels of p21106
	Wild type TSC-22 inhibits cell growth and leads to
	increased levels of p21 but not keratin 20 108 Overexpression of dominant negative TSC-22 partially inhibits PPARγ ligand and TGF-β1 induced growth inhibition
	and p21 induction
	Conclusion 109
VII.	DISCUSSION112
	Activation of PPARγ inhibits colorectal cancer cell growth112Target genes of PPARγ in colorectal cancer cells113A loss of function allele in colorectal cancer cells caused by113
	mutation that disrupts basal transcriptional repression
VIII.	FUTURE AIMS125
	Future Aims
REFE	RENCES

## LIST OF TABLES

Table		Page
1.	PPAR target genes with identified PPREs	3
2.	Summary of genes induced or repressed after exposure of M-S colon carcinoma cells to the PPARy ligand rosiglitazone	68
3.	PPARγ ligand sensitivity and PPARγ receptor mutations in a panel of human colorectal cancer cell lines	81

## LIST OF FIGURES

Figure		Page
1.	The DNA binding motif of NHRs and NHR classification	3
2.	Anatomy of NHRs	7
3.	Transcriptional activities of NHRs and the coregulatory exchange	11
4.	Overview of PPARs	15
5.	PPARγ ligands	20
6.	Metabolic consequences of PPARy activation	25
7.	The cyclooxygenase signaling cascade	29
8.	PPAR $\gamma$ is expressed and functionally active in colorectal cancer cells	54
9.	Rosiglitazone inhibits cell growth of colon cancer cells in vitro	55
10.	The PPARy selective agonist rosiglitazone inhibits anchorage independent growth of cells that express functional PPARy	57
11.	Rosiglitazone reduces the volume of tumors grown in vivo from cells expressing functional PPARy	59
12.	PPARγ activation induces G <sub>1</sub> cell cycle arrest	60
13.	PPARγ is expressed and transcriptionally active in the M-S colon carcinoma line	65
14.	PPARγ specifically and selectively inhibits the growth of the M-S colon carcinoma line	66
15.	The PPAR $\gamma$ target genes adipopohilin and L-FABP are also targets of PPAR $\alpha$ and/or PPAR $\delta$	70
16.	The PPARγ target genes RegIA, Gob-4, NGAL, and keratin 20 are specifically and selectively regulated by PPARγ	71
17.	PPARγ induces three different members of the CEA family of proteins	73

18.	PPAR $\gamma$ ligands induce an increase in CEA-dependent	74
		/4
19.	Expression of PPARy in human colorectal caner cell lines	80
20	DNA binding and transcriptional activity of K422Q PPARγ	83-4
21.	Generation of HCT 15 colorectal cancer cells expressing WT or K422Q PPARγ by retroviral transduction	86
22.	Expression of WT, but not K422Q, PPAR $\gamma$ causes the previously resistant HCT 15 cell lines to become sensitive to PPAR $\gamma$ agonist-induced G <sub>1</sub> delay and growth inhibition <i>in vitro</i>	87
23.	K422Q PPARγ is defective in repressing the basal expression target genes in the absence of exogenous ligand	89
24.	There is no difference between WT and K422Q PPARγ in binding affinity to the corepressors N-CoR or SMRT in solution	91
25.	The PPAR $\gamma$ ligand rosiglitazone or TGF- $\beta$ 1 induces growth inhibition and increases in protein levels of p21 in a panel of colon epithelial cell lines.	96-7
26.	TSC-22 is a downstream target of both PPARγ and TGF-β1 in colon epithelial cells	98
27.	TSC-22 is localized to the post-mitotic epithelial compartment of the normal human colon	. 99
28.	Time and dose dependent induction of TSC-22 by PPAR $\gamma$ and TGF- $\beta$ 1	101
29.	TSC-22 is a direct target of PPARγ	102
30.	TSC-22 is specifically and selectively induced by PPARγ	104
31.	The induction of TSC-22 by PPARγ is not dependent on an intact TGF-β1 signaling pathway	105
32.	Dominant negative TSC-22 blocks the ability of PPAR $\gamma$ or TGF- $\beta$ to induce p21 and inhibit cell growth	110